ANOZOAOFIA KAPKINOY FINEYMONA


LUNG CANCER IMMUNOLOGY

Βαίος Καρανίκας EU Marie Curie Fellow Μονάδα Ανοσολογίας Καρκίνου Εργαστήριο Ανοσολογίας-Ιστοσυμβατότητας Τμήμα Ιατρικής – Πανεπιστήμιο Θεσσαλίας


David Hunt. Cell Systems Initiative, U. of Washington.

Immune cells (white) attacking cancer cell

T cell activation and tumour lysis




T cell activation and tumour lysis




The Immunosurveillance theory

The Three E's




Dunn, Old, Shroeber et al; Nature Immunology 2002




The Immunosurveillance theory

The Three E's




Dunn, Old, Shroeber et al; Nature Immunology 2002



The Immunosurveillance theory

The Three E's



Dunn, Old, Shroeber et al; Nature Immunology 2002

Immune response

Tumour

Therapeutic Vaccines - Problems

No strong clinical response


(~**3%** of vaccinated patients regress for short term)

Lack of detection of spontaneous & vaccine induced immune responses

(-understanding TAA expression and immune profile) (-access, resistance to lysis, suppressive factors, tolerance....)

IRTALUNG

Evaluation of Immune Responses Against Highly Expressed Tumor Antigens in Non-Small Cell Lung Cancer; Prospects for Immunotherapy



Lung cancer Tumour Immunology

T cells are present in tumour infiltrates

No Lung Cancer specific antigen identified

T cells against mutated Ag, hTERT, CEA etc


IRTALUNG Objective/Aim

To explore the expression profile of TAA in patients with lung cancer

AND

to determine the strength and the quality of the immune response against them

IRTALUNG Experimental design Part 1: Cellular Immune response analysis




TCR seq ?

T lymphocyte

Karanikas et al; J Immunol 2003

IRTALUNG Experimental design Part 2:- Tumour Antigen expression analysis


- Immunoregulatory molecule analysis



IRTALUNG

IRTALUNG Results

T cell response



 Frequency amongst peripheral CD8 T cells up to which analysis was achieved and no clone could be detected

The frequency at which the clone was detected

IRTALUNG Outcomes/Perspectives

- **TAA expression profile** (real time PCR, Ag)
- CTL responses in normal individuals and patients with cancer (central & peripheral tolerance?)
- CTL response against multipe epitopes of self antigens (role?)
- Functional characteristics of CTL

IRTALUNG-> Cancer IMMUNOEPIGENETICS

Cancer is a systemic disease that can possibly affect the immune system and the mechanisms involved in the anti-tumour response

Department of Immunology and Histocombatibility Prof Anastasios Germenis

Cancer Immunology Unit

Dr Vaios Karanikas

Kalala F Tsohas S Loules G Argentou N Vardakastani N Gramoustianou E Zamanakou M Khalil S Siska E Soukou F Boukas K

Collaborators

- Respiratory Medicine Department, UTH: Prof Gourgoulianis K, Kerenidi N


A share as

- Thoracic Surgery Department, UTH: Dr Hevas A
- Department of Pathology, UTH: Prof Koukoulis G, Nakou M
- Genetic and Cellular Unit, Ludwig Institute for Cancer Research, Belgium: Prof Coulie
- Cancer Trials Laboratory, Austin Research Institute, Melbourne, Australia: Prof. Loveland
- 2nd Department of Surgery, University of Kitakyushu, Japan: M. Takenoyama

Funding


EU, GSRT, GSK, Pfizer

Tumour development




Considerations


Spontaneous antitumor T cell response



Vaccination followed by regression




Considerations



C. Uptake of antigens by DC and presentation to TIL


T cell activation and tumour Lysis



Lung cancer Tumour Immunology

- T cells are present in tumour infiltrates •
- No Lung Cancer specific antigen identified
- T cells against mutated Ag, hTERT, CEA etc

Labeling anti-malic T lymphocytes with tetramers



Karanikas et al; Cancer Res 2001